Efficacy of Immunoglobulin Plus Infliximab for the Early Regression of Coronary Artery Lesion in Kawasaki Disease

Phase 3 Withdrawn Children's Hospital of Fudan University Shanghai 10th People's Hospital · collab Shanghai Children's Hospital · collab Shanghai Children's Medical Center · collab Xinhua Hospital, Shanghai Jiao Tong University School of Medicine · collab

RandomizedParallel-groupSingle-blindTreatment

Summary

This study evaluates the efficacy of the addition of infliximab to conventional initial treatment (intravenous immunoglobulin \[IVIG\] plus aspirin) in early regression of coronary artery lesion in patients with Kawasaki disease (KD).

Timeline

Start: 2020-10
Primary completion: 2022-09
Completion: 2022-09

Publications

Background Dallaire F, Dahdah N. New equations and a critical appraisal of coronary artery Z scores in healthy children. J Am Soc Echocardiogr. 2011 Jan;24(1):60-74. doi: 10.1016/j.echo.2010.10.004. Epub 2010 Nov 13.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Infliximab	Monoclonal antibody	5 mg/kg	Intravenous
Background	Aspirin	Small molecule	3 mg/kg	Oral
Background	Aspirin	Small molecule	5 mg/kg	Oral
Background	Aspirin	Small molecule	30 mg/kg	Oral
Background	Immune Globulin Intravenous (Human)	Protein / enzyme biologic	2 g/kg	Intravenous

Efficacy of Immunoglobulin Plus Infliximab for the Early Regression of Coronary Artery Lesion in Kawasaki Disease

Summary

Timeline

Publications

Drugs

Indications